Related Experiment Video
Updated: Jan 28, 2026

Isolation and Culture of Primary Oral Keratinocytes from the Adult Mouse Palate
Published on: September 24, 2021
Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor
Maria Monica Haydock1, Shahed Elhamdani2, Mohamed Alsharedi3
1Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
Abstract:
Osteonecrosis is a pathological condition that could lead to a debilitating physical disease and impede daily activities. It is generally categorised into aetiology - primary (idiopathic) or secondary. When direct damage to the bone vasculature or direct injury of the bone marrow is related to an identifiable cause such as traumatic injuries, steroid or bisphosphonate use, increased alcohol intake, sickle cell disease, autoimmune diseases, chemotherapy or malignancy, it is categorised as secondary osteonecrosis. On the other hand, osteonecrosis wherein the mechanisms of development are not fully understood is categorised as primary or idiopathic osteonecrosis. This category includes inherited thrombophilia and hypofibrinolysis as potential causes. There are no clear guidelines or general agreements about anticoagulation treatment and duration in primary osteonecrosis due to thrombophilia or hypofibrinolysis. We report a case of primary osteonecrosis associated with hypofibrinolysis and successful control with lifelong direct oral anticoagulation therapy.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Directional Terms
Primary Active Transport
Primary Active Transport
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Antihypertensive Drugs: Direct Renin Inhibitors

